التفاصيل البيبلوغرافية
| العنوان: |
Management of high-grade gliomas in the pediatric patient: Past, present, and future. |
| المؤلفون: |
Vanan, Magimairajan Issai1, Eisenstat, David D.1 |
| المصدر: |
Neuro-Oncology Practice. Dec2014, Vol. 1 Issue 4, p145-157. 13p. |
| مصطلحات موضوعية: |
*GLIOMAS, *PEDIATRIC research, *TUMORS in children, *PEDIATRIC surgery, BRAIN tumor diagnosis |
| مستخلص: |
High-grade gliomas (HGGs) constitute ∼15% of all primary brain tumors in children and adolescents. Routine histopathological diagnosis is based on tissue obtained from biopsy or, preferably, from the resected tumor itself. The majority of pediatric HGGs are clinically and biologically distinct from histologically similar adult malignant gliomas; these differences may explain the disparate responses to therapy and clinical outcomes when comparing children and adults with HGG. The recently proposed integrated genomic classification identifies 6 distinct biological subgroups of glioblastoma (GBM) throughout the age spectrum. Driver mutations in genes affecting histone H3.3 (K27M and G34R/V) coupled with mutations involving specific proteins (TP53, ATRX, DAXX, SETD2, ACVR1, FGFR1, NTRK) induce defects in chromatin remodeling and may play a central role in the genesis of many pediatric HGGs. Current clinical practice in pediatric HGGs includes surgical resection followed by radiation therapy (in children aged > 3 years) with concurrent and adjuvant chemotherapy with temozolomide. However, these multimodality treatment strategies have had a minimal impact on improving survival. Ongoing clinical trials are investigating new molecular targets, chemoradiation sensitization strategies, and immunotherapy. Future clinical trials of pediatric HGG will incorporate the distinction between GBM molecular subgroups and stratify patients using group-specific biomarkers. [ABSTRACT FROM PUBLISHER] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder